Christopher Dumont
Overview
Christopher Dumont is an associate in Crowell & Moring’s Brussels office and is a member of the Intellectual Property Group.
Christopher advises and assists clients in both contentious and noncontentious matters across the broad spectrum of IP/IT law. He also advises on commercial law and regulatory matters. Christopher has experience in advising and litigating complex trademark and patent litigation cases, including procedural aspects (e.g., use without due cause, Bolar exemption, Arrow declarations, priority rights, Gillette defense, locus standi). He has handled parallel import cases and European cross-border issues and advised on regulatory matters, IP portfolio management, and strategic planning.
Career & Education
- Catholic University of Leuven, B.A., honours program, 2015
- Catholic University of Leuven, J.D., honours program, 2017
- Catholic University of Leuven, LL.M., intellectual property law, 2018
- Belgium
- European Court
- Dutch
- English
- French
Kristof Roox and Christopher Dumont are able to deliver within tight deadlines. They bring innovative ways to help customers, excellent collaboration within a group of customers. Clear when conveying information and summaries.
— Legal 500, 2024
Christopher's Insights
Client Alert | 6 min read | 07.30.25
The new EU “Pharma Package”: Global (Orphan) Marketing Authorization
In this fifth alert in our weekly series on the EU Pharma Package, we will delve into the global marketing authorization (GMA) concept which has largely remained untouched in the legislative proposal – aside from an important introduction of the notion of a GMA for orphan medicinal products. We will discuss the missed opportunity to codify existing case law and provide further clarification in this respect.
Client Alert | 9 min read | 07.09.25
Client Alert | 3 min read | 06.30.25
Firm News | 3 min read | 05.30.25
Representative Matters
- Assisting leading pharmaceutical companies in preliminary injunction proceedings regarding generic versions of blockbuster medicinal products.
- Assisting one of the largest tobacco companies in a multilayered cross-border trademark litigation against a spread-out network of infringers.
- Assisting a leading financial company in the development and maintenance of their trademark portfolio.
- Assisting a major Belgian book publisher in complex litigation and investigation by court-appointed expert concerning the publishing and audiovisual rights attached to a graphic character.
- Negotiating a global software license for a consortium of companies in the recycling industry.
- Assisting a European public-private partnership with the supply of data protection and related services.
Christopher's Insights
Client Alert | 6 min read | 07.30.25
The new EU “Pharma Package”: Global (Orphan) Marketing Authorization
In this fifth alert in our weekly series on the EU Pharma Package, we will delve into the global marketing authorization (GMA) concept which has largely remained untouched in the legislative proposal – aside from an important introduction of the notion of a GMA for orphan medicinal products. We will discuss the missed opportunity to codify existing case law and provide further clarification in this respect.
Client Alert | 9 min read | 07.09.25
Client Alert | 3 min read | 06.30.25
Firm News | 3 min read | 05.30.25
Recognition
IAM Patent 1000: Litigation and Transactions, Recommended, 2025
Christopher's Insights
Client Alert | 6 min read | 07.30.25
The new EU “Pharma Package”: Global (Orphan) Marketing Authorization
In this fifth alert in our weekly series on the EU Pharma Package, we will delve into the global marketing authorization (GMA) concept which has largely remained untouched in the legislative proposal – aside from an important introduction of the notion of a GMA for orphan medicinal products. We will discuss the missed opportunity to codify existing case law and provide further clarification in this respect.
Client Alert | 9 min read | 07.09.25
Client Alert | 3 min read | 06.30.25
Firm News | 3 min read | 05.30.25
Insights
Standing to litigate and effects on remedies
|01.01.20
ICIP 2020, Vol. 2, 317-359
Practices
- Intellectual Property — Brussels Practice
- Intellectual Property Litigation
- Dispute Resolution — Brussels Practice
- Intellectual Property
- Digital Advertising
- Technology, Media, and Telecommunications — Brussels Practice
- Brussels Practice
- Digital Health and Health Information Technology
- Life Sciences — Intellectual Property
- Life Sciences
- Life Sciences — Brussels Practice
Industries
Christopher's Insights
Client Alert | 6 min read | 07.30.25
The new EU “Pharma Package”: Global (Orphan) Marketing Authorization
In this fifth alert in our weekly series on the EU Pharma Package, we will delve into the global marketing authorization (GMA) concept which has largely remained untouched in the legislative proposal – aside from an important introduction of the notion of a GMA for orphan medicinal products. We will discuss the missed opportunity to codify existing case law and provide further clarification in this respect.
Client Alert | 9 min read | 07.09.25
Client Alert | 3 min read | 06.30.25
Firm News | 3 min read | 05.30.25
